MedTrace Logo

MRE-IA in Liver Disease and Neurovascular Imaging

NCT03601845 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 59

Last updated 2020-02-11

No results posted yet for this study

Summary

The objective of this research project is to develop Magnetic Resonance Elastography by Intrinsic Activation (MRE-IA) imaging methods at two imaging centers (CRCHUS and CRCHUM) for use in ongoing studies in liver disease and neurovascular imaging. MRE is a developing MR imaging modality that provides detailed maps of tissue's mechanical properties, based on displacement measurements made during the propagation of low amplitude vibrations through the region of interest. MRE-IA uses the pressure pulses of the cardiac cycle to induce the vibrations needed for MRE image reconstruction.

MRE-IA has already been demonstrated based on the use of existing, clinically approved MR imaging sequences, and once this capability has been established at the two centers, initial trials will be done to demonstrate the method's potential in liver and neurovascular imaging. In the case of the liver, this pilot project funding will be used to perform MRE-IA imaging in patients with chronic liver disease and focal liver lesions. Results will be analyzed to establish the relationship between the mechanical properties mentioned above and disease stage. In the neurovascular case, imaging will be conducted under basic visual and motor stimulus conditions in healthy subjects, and results compared non-stimulus control images to determine changes in the above properties based on brain function. In addition, MRE-IA images will be compared with BOLD imaging to investigate the role of fluid conductivity in fMRI results.

Conditions

  • Diffuse and Focal Liver Diseases, Cerebral Function

Interventions

OTHER

Stimuli

Visual stimulation while using additional sequencing

OTHER

No stimuli

Additional sequencing only

Sponsors & Collaborators

  • Centre hospitalier de l'Université de Montréal (CHUM)

    collaborator OTHER

  • Réseau de bio-imagerie du Québec (RBIQ)

    collaborator UNKNOWN

  • Université de Sherbrooke

    lead OTHER

Principal Investigators

  • Van Houten Elijah, Ing., PhD · Centre hospitalier de l'Université de Sherbrooke

Study Design

Allocation
NON_RANDOMIZED
Purpose
DIAGNOSTIC
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
100 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2019-01-31
Primary Completion
2019-07-01
Completion
2019-07-01

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03601845 on ClinicalTrials.gov